Enliven Therapeutics, Inc (ELVN) revealed Loss for its second quarter of -$25.34 million
The company's bottom line totaled -$25.34 million, or -$0.49 per share. This compares with -$19.95 million, or -$0.41 per share, last year.
Enliven Therapeutics, Inc earnings at a glance (GAAP) :
-Earnings: -$25.34 Mln. vs. -$19.95 Mln. last year.-EPS: -$0.49 vs. -$0.41 last year.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.